TikoMed is focused on developing innovative treatments and cell therapies aimed at addressing severe and life-threatening conditions, particularly in the fields of neurology and ophthalmology. One of their key drug candidates, ILB®, is designed to activate the body's natural repair mechanisms and has shown promise in treating neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). The company has conducted clinical trials that confirm the safety and tolerability of ILB®, suggesting its potential as a disease-modifying treatment with minimal side effects. TikoMed's approach emphasizes the orchestration of the body's signaling pathways to enhance tissue repair, which could provide new hope for patients with limited treatment options.

In addition to ILB®, TikoMed is also advancing IBSOLVMIR, a cell therapy that aims to improve the efficacy of existing cell therapies. The company has established research collaborations with prominent institutions, such as the Division of Clinical Neuroscience at Oslo University Hospital, to further explore and validate their treatment options. TikoMed's commitment to scientific research and collaboration underscores its goal of delivering groundbreaking therapies that can significantly improve patient outcomes in the face of challenging medical conditions.

Norway

We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our products have the potential to improve outcomes in the treatment of neurological and opthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.

TikoMed

Company Details